Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
INFECTIOUS DISEASES / RESEARCH LETTER
Efficacy of linezolid in the treatment of tuberculous meningitis: a meta-analysis
1
Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China
2
Department of Respiratory and Critical Care Medicine, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China
3
State Key Laboratory of Respiratory Health and Multimorbidity, China
Submission date: 2024-05-03
Final revision date: 2024-06-01
Acceptance date: 2024-06-11
Online publication date: 2024-06-29
Corresponding author
Jian-Qing He
Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University,, No. 37, Guo Xue Alley, 610041, Chengdu, China
Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University,, No. 37, Guo Xue Alley, 610041, Chengdu, China
Arch Med Sci 2024;20(3):1038-1042
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Tuberculous meningitis (TBM) is a severe extra-pulmonary tuberculosis with high fatality. This meta-analysis aimed to assess the impact of linezolid on TBM treatment outcomes.
Methods:
We searched multiple databases for studies published up to May 18, 2024 comparing the effects of linezolid on TBM. Meta-analysis was conducted using Review Manager 5.4.
Results:
Our findings indicated that linezolid may reduce treatment failure risk (RR = 0.42 (0.20, 0.89), p = 0.02) and improve temperature recovery (RR = 1.56 (1.21, 2.02), p < 0.001) in TBM patients.
Conclusions:
The analysis suggests a positive association between linezolid treatment and therapeutic improvements, with no significant adverse reactions reported.
Tuberculous meningitis (TBM) is a severe extra-pulmonary tuberculosis with high fatality. This meta-analysis aimed to assess the impact of linezolid on TBM treatment outcomes.
Methods:
We searched multiple databases for studies published up to May 18, 2024 comparing the effects of linezolid on TBM. Meta-analysis was conducted using Review Manager 5.4.
Results:
Our findings indicated that linezolid may reduce treatment failure risk (RR = 0.42 (0.20, 0.89), p = 0.02) and improve temperature recovery (RR = 1.56 (1.21, 2.02), p < 0.001) in TBM patients.
Conclusions:
The analysis suggests a positive association between linezolid treatment and therapeutic improvements, with no significant adverse reactions reported.
REFERENCES (19)
1.
Seddon JA, Tugume L, Solomons R, Prasad K, Bahr NC. The current global situation for tuberculous meningitis: epidemiology, diagnostics, treatment and outcomes. Wellcome Open Res 2019; 4: 167.
2.
Thwaites GE, van Toorn R, Schoeman J. Tuberculous meningitis: more questions, still too few answers. Lancet Neurol 2013; 12 :999-1010.
3.
World Health Organization & World Health Organization. (2010). Treatment of tuberculosis: guidelines, 4th edition. World Health Organization. https://iris.who.int/handle/10....
4.
Abulfathi AA, Decloedt EH, Svensson EM, Diacon AH, Donald P, Reuter H. Clinical pharmacokinetics and pharmacodynamics of rifampicin in human tuberculosis. Clin Pharmacokinet 2019; 58: 1103-29.
5.
Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis 2010; 90: 279-92.
6.
Sahib A, Bhatia R, Srivastava MVP, et al. Escalate: Linezolid as an add on treatment in the intensive phase of tubercular meningitis. A randomized controlled pilot trial. Tuberculosis 2023; 142: 102351.
7.
Sun F, Ruan Q, Wang J, et al. Linezolid manifests a rapid and dramatic therapeutic effect for patients with life-threatening tuberculous meningitis. Antimicrob Agents Chemother 2014; 58: 6297-301.
8.
Li H, Lu J, Liu J, Zhao Y, Ni X, Zhao S. Linezolid is associated with improved early outcomes of childhood tuberculous meningitis. Pediatr Infect Dis J 2016; 35: 607-10.
9.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 6: e1000097.
10.
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
11.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
12.
Fang MT, Su YF, An HR, et al. Decreased mortality seen in rifampicin/multidrug-resistant tuberculous meningitis treated with linezolid in Shenzhen, China. BMC Infect Dis 2021; 21: 1015.
13.
Aktas G. Activity of vancomycin combined with linezolid against clinical vancomycin-resistant Enterococcus strains. Arch Med Sci 2023; 19: 189-93.
14.
Bigelow KM, Deitchman AN, Li SY, et al. Pharmacodynamic correlates of linezolid activity and toxicity in murine models of tuberculosis. J Infect Dis 2021; 223: 1855-64.
15.
Davis AG, Wasserman S, Stek C, et al. A phase 2a trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for human immunodeficiency virus-associated tuberculous meningitis: the LASER-TBM trial. Clin Infect Dis 2023; 76: 1412-22.
16.
Mazanhanga M, Joubert A, Castel S, et al. Validation of a quantitative liquid chromatography tandem mass spectrometry assay for linezolid in cerebrospinal fluid and its application to patients with HIV-associated TB-meningitis. Heliyon 2023; 9: e21962.
17.
Perdigão J, Maltez F, Machado D, et al. Beyond extensively drug-resistant tuberculosis in Lisbon, Portugal: a case of linezolid resistance acquisition presenting as an iliopsoas abscess. Int J Antimicrob Agents 2016; 48: 569-70.
18.
Esmail A, Oelofse S, Lombard C, et al. An all-oral 6-month regimen for multidrug-resistant tuberculosis: a multicenter, randomized controlled clinical trial (the NExT Study). Am J Respir Crit Care Med 2022; 205: 1214-27.
19.
Graciaa DS, Kipiani M, Magee MJ, et al. Linezolid exposure is associated with cytopenias in patients treated for multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2022; 66: e0040822.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
